BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $23.56 -0.05 (-0.22%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$23.58 +0.02 (+0.07%) As of 08/1/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsBuy This Stock About ARK Genomic Revolution ETF (BATS:ARKG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARKG alerts:Sign Up Key Stats Today's Range$24.20▼$25.2450-Day Range$20.94▼$26.5652-Week Range$17.51▼$31.16Volume4.90 million shsAverage Volume2.73 million shsMarket Capitalization$1.05 billionAssets Under Management$1.01 billionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK. Read More ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.57%0.53%Other Expenses0.00%0.57%0.56%0.48%0.56%Total Expense0.75%0.74%0.76%0.71%0.73%Fee Waiver0.00%-0.76%-0.66%-0.46%-0.63%Net Expense0.75%0.60%0.63%0.64%0.60% Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address ARKG ETF News HeadlinesWhy Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)July 25, 2025 | finance.yahoo.comARKG: April's Wash-Out Low Is Encouraging, Healthcare Still SoftJuly 25, 2025 | seekingalpha.comOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas. | InvestorPlace (Ad)ARK Genomic Revolution ETF (ARKG) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comCathie Wood shells out $13.9 million for one high-stakes biotech stockJuly 8, 2025 | msn.comARK Genomic Revolution ETF (ARKG) Risk - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comSee More Headlines ARKG ETF - Frequently Asked Questions How have ARKG shares performed this year? ARK Genomic Revolution ETF's stock was trading at $23.5450 at the start of the year. Since then, ARKG shares have increased by 0.1% and is now trading at $23.5590. Who are ARK Genomic Revolution ETF's major shareholders? Top institutional shareholders of ARK Genomic Revolution ETF include Kingstone Capital Partners Texas LLC (0.35%), Brookstone Capital Management (0.12%), Envestnet Asset Management Inc. (0.11%) and Wealthfront Advisers LLC (0.10%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARK Genomic Revolution ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARK Genomic Revolution ETF investors own include Invesco QQQ (QQQ), ARK Innovation ETF (ARKK), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AbbVie (ABBV) and PayPal (PYPL). Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings36 Fund Statistics Assets Under Management$1.01 billion Average Daily Volume$2.55 million Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorARK Investment Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume12,253 Put Options8,578 Call Options3,675 Miscellaneous Outstanding Shares44,700,000Beta1.62 Creation Unit50,000 Creation Fee$500.00 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Top 10 ARKG HoldingsCRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 11.04%Tempus AI (NASDAQ:TEM)Holding Weight: 9.23%Twist Bioscience (NASDAQ:TWST)Holding Weight: 7.30%Recursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 6.15%Guardant Health (NASDAQ:GH)Holding Weight: 5.72%Natera (NASDAQ:NTRA)Holding Weight: 4.59%Personalis (NASDAQ:PSNL)Holding Weight: 4.39%Schrodinger (NASDAQ:SDGR)Holding Weight: 4.04%Beam Therapeutics (NASDAQ:BEAM)Holding Weight: 4.03%10x Genomics (NASDAQ:TXG)Holding Weight: 3.93%Full Holdings DetailsARKG Sector ExposureARKG Industry Exposure This page (BATS:ARKG) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.